Citation
Chae, Y S., et al. "New Myeloablative Conditioning Regimen With Fludarabine and Busulfan for Allogeneic Stem Cell Transplantation: Comparison With BuCy2." Bone Marrow Transplantation, vol. 40, no. 6, 2007, pp. 541-7.
Chae YS, Sohn SK, Kim JG, et al. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2. Bone Marrow Transplant. 2007;40(6):541-7.
Chae, Y. S., Sohn, S. K., Kim, J. G., Cho, Y. Y., Moon, J. H., Shin, H. J., Chung, J. S., Cho, G. J., Yang, D. H., Lee, J. J., Kim, Y. K., & Kim, H. J. (2007). New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2. Bone Marrow Transplantation, 40(6), 541-7.
Chae YS, et al. New Myeloablative Conditioning Regimen With Fludarabine and Busulfan for Allogeneic Stem Cell Transplantation: Comparison With BuCy2. Bone Marrow Transplant. 2007;40(6):541-7. PubMed PMID: 17637692.
TY - JOUR
T1 - New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
AU - Chae,Y S,
AU - Sohn,S K,
AU - Kim,J G,
AU - Cho,Y Y,
AU - Moon,J H,
AU - Shin,H J,
AU - Chung,J S,
AU - Cho,G J,
AU - Yang,D H,
AU - Lee,J-J,
AU - Kim,Y-K,
AU - Kim,H-J,
Y1 - 2007/07/16/
PY - 2007/7/20/pubmed
PY - 2007/12/6/medline
PY - 2007/7/20/entrez
SP - 541
EP - 7
JF - Bone marrow transplantation
JO - Bone Marrow Transplant
VL - 40
IS - 6
N2 - A regimen of busulfan and cyclophosphamide (BuCy2) is regarded as the standard myeloablative regimen for SCT. This study evaluated the hypothesis that fludarabine can replace cyclophosphamide for myeloablative allogeneic SCT. Ninety-five patients underwent allogeneic SCT from HLA-identical donors, following BuCy2 (n=55) or busulfan+fludarabine (BF, n=40). The efficacy of fludarabine compared to cyclophosphamide was retrospectively evaluated. The BF group exhibited a shorter duration until engraftment (P=0.001), lower incidence of acute and chronic GVHD (P<0.001 and P=0.003, respectively), and non-relapse mortality (NRM) (P=0.039). Furthermore, the event-free survival and overall survival were significantly higher for the BF group compared to the BuCy2 group (P=0.004 and 0.002, respectively). After adjusting for age, the risk status of disease, GVHD prophylaxis and donor type, the BF regimen was found to be an independent favorable risk factor for event-free survival (hazard ratio (HR), 0.181; 95% confidence interval, 0.045-0.720; P=0.016) and overall survival (HR, 0.168; 0.035-0.807; P=0.026). The replacement of cyclophosphamide with fludarabine for myeloablative conditioning seems to be more effective in terms of short-term NRM, and GVHD compared to BuCy2 regimen in allogeneic transplantation.
SN - 0268-3369
UR - https://www.unboundmedicine.com/medline/citation/17637692/New_myeloablative_conditioning_regimen_with_fludarabine_and_busulfan_for_allogeneic_stem_cell_transplantation:_comparison_with_BuCy2_
L2 - https://doi.org/10.1038/sj.bmt.1705770
DB - PRIME
DP - Unbound Medicine
ER -